Differences on the Inhibitory Specificities of H-Ras, K-Ras, and N-Ras (N17) Dominant Negative Mutants Are Related to Their Membrane Microlocalization*

Revised manuscript received for publication, September 24, 2002, and in revised form, November 19, 2002. Published, JBC Papers in Press, November 27, 2002, DOI 10.1074/jbc.M209807200

David Matallanas‡, Imanol Arozarena‡§, María T. Berciano, David S. Aaronson‡‡

Angel Pellicer‡‡‡, Miguel Lafargue, and Piero Crespo‡‡‡‡

Department of Molecular and Anatomical Biology, Universidad de Cantabria, Santander 39011, Spain, the Department of Pathology and Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016, and the Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas, Arturo Duperier 4, Madrid 28029, Spain

Ras GTPases include the isoforms H-Ras, K-Ras, and N-Ras. Despite their great biochemical and biological similarities, evidence is mounting suggesting that Ras proteins may not be functionally redundant. A widespread strategy for studying small GTPases is the utilization of dominant inhibitory mutants that specifically block the activation of their respective wild-type proteins. As such, H-Ras N17 has proved to be extremely valuable as a tool to probe Ras functions. However, a comparative study on the inhibitory specificities of H-, K-, and N-Ras N17 mutants has not been approached thus far. Herein, we demonstrate that H-, K-, and N-Ras N17 mutants exhibit markedly distinct inhibitory effects toward H-, K-, and N-Ras. H-Ras N17 can effectively inhibit the activation of all three isoforms. K-Ras N17 completely blocks the activation of K-Ras and is only slightly inhibitory on H-Ras. N-Ras N17 can mainly inhibit N-Ras activation. In light of the recent data on the compartmentalization of H-Ras and K-Ras in the plasma membrane, here we present for the first time a description of N-Ras cellular microlocalization. Overall, our results on Ras N17 mutants specificities exhibit a marked correlation with the localization of the Ras isoforms to distinct membrane microdomains.

Received for publication, September 24, 2002, and in revised form, November 19, 2002.
Published, JBC Papers in Press, November 27, 2002, DOI 10.1074/jbc.M209807200

4572

This paper is available online at http://www.jbc.org
has been provided by gene targeting experiments. It has been found that N-ras knock-out mice develop and reproduce normally (20). H-ras knock-out animals are also normal (21). Strikingly, H- and N-ras double knock-outs also exhibit no detectable abnormalities (22). On the other hand, K-ras-deficient mice die during embryonic development (23, 24), suggesting that K-Ras possesses functions not shared by H- or N-Ras.

Recently, a considerable body of evidence has been accumulated suggesting that the aforementioned biochemical and biological differences among Ras isoforms could be due, in part, to variations in plasma membrane microlocalization (25). In this line, it has been shown that H-Ras is equally localized in caveolae, lipid rafts, and disordered membrane. By contrast, K-Ras is preferentially located in disordered, nonraft plasma membrane (26), although some may be present in caveolae depending on the cell type (27). Likewise, N-Ras localizes to caveolin-positive and caveolin-negative domains (27), but its detailed microlocalization has not been examined so far. Recent reports also demonstrate that all of the information required for membrane localization is contained in the hypervariable regions of the Ras isoforms (28, 29) that also dictate how Ras proteins traffic to their final locations. Whereas H- and N-Ras traffic to the plasma membrane along the secretory pathway through the Golgi complex, K-Ras4B is directly routed from the endoplasmic reticulum to the membrane by still unknown mechanisms (30, 31).

Multiple strategies have been utilized thus far to unveil the functions of Ras proteins in cells. Among these, the use of dominant inhibitory mutants is now widely established (32). Even since its identification (33, 34) the Ras mutant with a dominant inhibitory mutants is now widely established (32).

As controls, ultrathin sections were treated as described above but examined with a Philips EM208 electron microscope operated at 60 kV. PBS, 1% bovine serum albumin). After immunogold labeling, the ultrathin sections were treated as described above but examined with a Philips EM208 electron microscope operated at 60 kV.

**RESULTS**

To avoid misinterpretations, an initial requisite in this paper was to verify that the Ras isoforms under study were expressed in those cell lines to be utilized. Using antibodies that specifically recognize H-Ras, K-Ras, and N-Ras, we ascertained that these proteins were detectable in lysates from the cell lines to be utilized. Using antibodies that specifically recognize H-Ras, K-Ras, and N-Ras, we ascertained that these proteins were detectable in lysates from the cell lines to be utilized.
addition to MEK1 EE (1)

COS-7 cells co-transfected with HA-ERK2 (1)
formed using MBP as substrate, in anti-HA immunoprecipitates from ERK2 by Ras dominant inhibitory mutants. Kinase assays were per-
formed using antibodies that specifically recognize the three Ras isoforms.

WB
collected in PBS, and pellets were lysed in 250 µl of lysis buffer. The proteins were fractionated by PAGE, and Western blots (WB) were performed using antibodies that specifically recognize the three Ras isoforms. B, concentration-dependent inhibition of the activation of ERK2 by Ras dominant inhibitory mutants. Kinase assays were performed using MBP as substrate, in anti-HA immunoprecipitates from COS-7 cells co-transfected with HA-ERK2 (1 µg) and with vector (−) or with increasing concentrations (50, 100, 200, and 250 ng) of constructs encoding H-N17, K-N17, and N-N17 as indicated, and stimulated with EGF (100 ng/ml) for 5 min after 12 h of serum starvation. Lower panels, protein levels of H-N17, K-N17, and N-N17 as determined by immunoblotting using isoform-specific antibodies. The panels show the average activation relative to EGF-treated cells from three independent exper-
iments. C, expression levels of H-N17, K-N17, and N-N17 in total cellular lysates, resulting from transfection of 250 ng of their respective coding constructs, as determined by anti-Pan-Ras immunoblotting. D, effects of Ras dominant inhibitory mutants on the activation of ERK2 induced by MEK1. Kinase assays were performed in anti-HA immunoprecipitates from COS-7 cells transfected with HA-ERK2 (1 µg) in addition to MEK1 EE (1 µg) and plasmids encoding for H-N17, K-N17, and N-N17 (250 ng). Lower panel, protein levels of HA-ERK2 as deter-
mined by immunoblotting using an HA-specific antibody.

COS-7, NIH3T3, and MDCK cells (Fig. 1A), thereby validating these three cell lines for further experimentation. As a first approach to investigate the specificity of H-, K(4B)-, and N-Ras N17 mutants (referred to as H-N17, K-N17, and N-N17 hereafter), we compared the inhibitory potential that each of the Ras dominant interfering mutants displayed against a Ras-activating stimulus such as EGF (40). As a readout, we utilized the activation of ERK2, whose activation by EGF in COS-7 cells has been previously shown to be potently inhibited by the original H-N17 (41). For this purpose, COS-7 cells were tran-
siently transfected with HA-ERK2 and with increasing concentra-
tions of the three inhibitory mutants. Upon stimulation with EGF it was found that H-, K-, and N-N17 were capable of diminishing EGF-induced activation of ERK2, although to dif-
ferent extents. At the maximum expression levels, H-N17 caused a total repression on ERK2 activation, K-N17 inhibited EGF-induced ERK2 activity by 88%, and N-N17 exhibited the least inhibitory effect, only reaching a 55% inhibition (Fig. 1B). We also monitored the protein levels of the three N17 mutants using antibodies specific for H-, K-, and N-Ras, verifying that, in all three cases, the augmentation in their inhibitory effects correlated with an increase in their protein levels (Fig. 1B, bottom panels). Because intrinsic variations in the affinity of the Ras isoform-specific antibodies precluded a comparison of the isoforms protein levels, we also utilized a pan-Ras antibody that recognizes equally the three Ras isoforms to ascertain that variations in the inhibitory potential of the N17 mutants were not due to differences in their expression. As shown in Fig. 1C, the protein levels of the three N17 mutants, resulting from the transfection of 250 ng of their coding constructs, were similar. To make sure that the inhibitory effects of the Ras N17 mut-
ants were not due to some unspecific, Ras-independent process, we co-transfected a constitutively active mutant of MEK1 (MEK1), known to act downstream from Ras (36), with H-N17, K-N17 and N-N17 mutants. It was found that the activation of ERK2 by MEK1 was completely unaffected by the Ras inhibi-
tory mutants (Fig. 1D), thus verifying that the inhibitory effects of H-, K-, and N-Ras dominant interfering mutants were Ras-mediated.

It is well known that the inhibitory effects of Ras N17 can be overcome by the increased expression of wild-type Ras (34, 42). Therefore, we tested whether the inhibition of EGF-induced activation of ERK2 by H-, K-, and N-Ras inhibitory mutants could be rescued by an overexpression of their respective wild-
type proteins. As such, the cells were transfected with H-N17,
K-N17, and N-N17 in addition to increasing concentrations of plasmids encoding for their wild-type homologues. It was found that even at their lowest concentration, a 2-fold excess, H-, K-, and N-Ras wild types remarkably rescued the restrain exerted by their respective N17 mutants on the activation of ERK2 induced by EGF (Fig. 2). These rescues were not due to a direct activation of ERK2 by the wild-type Ras proteins, because even at their highest levels of expression, wild-type H-, K-, and N-Ras activated ERK2 very poorly (data not shown).

Next, we investigated whether the inhibitory effect exerted by a given Ras N17 mutant could be restored by the overexpression of any of the three wild-type Ras isoforms. For this purpose cells transfected with AU5-ERK2 were co-transfected with equal amounts of HA-tagged H-N17, K-N17, and N-N17 and of FLAG-tagged wild-type H-, K-, and N-Ras. Then ERK2 activation was determined in anti-AU5 immunoprecipitates upon EGF stimulation. The rescue of the dominant negative constructs by overexpression of the wild-type Ras proteins, because even at their highest levels of expression, wild-type H-, K-, and N-Ras activated ERK2 very poorly (data not shown).

Interestingly, the blockade on EGF-induced ERK2 activation brought about by H-N17 could only be effectively rescued by H-Ras, whereas K-Ras and N-Ras were solely capable of slight rescues of 12 and 16%, respectively (Fig 3A). These differences on the rescue capabilities of each Ras isoform could not be attributed to major differences on their relative protein concentrations, because the HA/FLAG ratio was almost identical in all cases (Fig. 3A, lower panels). In a similar fashion, the inhibitory effect exerted by K-N17 could be entirely overcome by H-Ras, and K-Ras was capable of a restoration up to 79%, whereas N-Ras was completely ineffective for rescuing the activation of ERK2 (Fig. 3B). Likewise, the inhibition caused by N-N17 was fully restored by N-Ras, and up to 78% was restored by H-Ras, but it was unaffected by the expression of K-Ras (Fig. 3C). These results constituted the first evidence for differential behavior of H-, K-, and N-Ras N17 mutants on their inhibitory properties.

We moved further to examine whether the membrane attachment signal could influence the ability of a Ras isoform to overcome the inhibitory effect of its respective N17 mutant. To do so, we generated an H-Ras in which cysteine 186 was de-
fraction; lane P, P100 particulate fraction. Right panel, ERK2 activation by H-Ras CAAX mutant proteins. Kinase assays from cells co-transfected with HA-ERK2 (1 μg), and the indicated Ras construct (500 ng, 100 ng for H-Ras V12), or stimulated with EGF (100 ng/ml) for 5 min, performed as previously described. B, rescue by Myr-H-ΔCAAX of the inhibition induced by H-N17. COS-7 cells were co-transfected with HA-ERK2 (1 μg), with vector (lanes c and –) and with 250 ng of H-N17 (lanes +), in addition to 500 ng of plasmids encoding for the different H-Ras proteins as indicated. Upon stimulation with EGF (100 ng/ml) for 5 min, the kinase assays were performed in anti-HA immunoprecipitates, using MBP as substrate. C, rescue by myristoylated N-Ras of the inhibition induced by H-N17. COS-7 cells were co-transfected with HA-ERK2 (1 μg), with vector (lanes c and –) and with 250 ng of H-N17 (lanes +), in addition to 500 ng of plasmids encoding for the different Ras proteins as indicated. Upon stimulation with EGF (100 ng/ml) for 5 min, the kinase assays were performed in anti-HA immunoprecipitates, using MBP as substrate.
specificity of H-Ras, K-Ras, and N-Ras N17 Mutants

Fig. 5. Inhibition of nucleotide exchange on Ras isoforms by H-, K-, and N-Ras N17 mutants. A, inhibition of nucleotide exchange on K-Ras by H-N17, K-N17, and N-N17. Ras GTP loading was determined as described under “Materials and Methods” upon treatment with EGF (100 ng/ml) for 5 min where indicated, in COS-7 cells co-transfected with HA-K-Ras (250 ng) in the presence of vector (−) or of H-N17, K-N17, and N-N17 (250 ng of each) as shown. Upper panel, HA-K-Ras-GTP levels from a representative experiment, as determined by anti-HA-immunoblotting in affinity precipitates using GST-Raf. Lower panel, total input, K-Ras levels as determined by anti-HA-immunoblotting in total lysates. B, lower panel, protein levels of AU5-tagged H-N17, K-N17, and N-N17 as determined by anti-AU5 immunoblotting. The numbers show the ratio of the HA/AU5 signals in a representative experiment. C, inhibition of nucleotide exchange on N-Ras by H-N17, K-N17, and N-N17. A–C, data show averages ± S.E. of at least five independent experiments. D, effects of Ras inhibitory mutants on EGF-induced ERK2 activation in N-Ras-null MEFs. MEFs from N-Ras-null mice (−/−) and wild-type littermates (+/+ ) were transiently co-transfected with HA-ERK2 (1 μg) and AU5-tagged H-N17, K-N17, and N-N17 (250 ng of each). Upon stimulation with EGF (100 ng/ml) for 5 min where indicated (+), kinase assays were performed as previously described. Lower panels, protein levels of HA-ERK2 and AU5-tagged inhibitory mutants as determined by immunoblotting using anti-HA and AU5-specific antibodies, respectively. WB, Western blot.

exhibited by H-, K-, and N-Ras dominant interfering mutants guarded some relationship with the pattern of distribution of the three Ras isoforms in different plasma membrane microdomains. The compartmentalization of H-Ras and K-Ras is well documented, whereas H-Ras is mainly found in lipid rafts, both caveolar and noncaveolar, K-Ras is present in the bulk, disordered membrane (26, 27, 31, 45). However, a detailed study on N-Ras cellular distribution is still missing. As a first approach to ascertain the nature of the plasma membrane microlocations where N-Ras was positioned, we carried out a Triton X-100 solubility test to assay for lipid raft association, because lipid rafts are insoluble in this detergent (26). As such, COS-7 cells were transfected with HA-tagged K-Ras and N-Ras, and their solubility in 0.25% Triton X-100 was determined as described under “Materials and Methods.” The presence of the Ras isoforms in the different fractions was analyzed by anti-HA immunoblotting. Anti-caveolin-1 immunoblotting identifies the lipid raft fractions. WB, Western blot; wt, wild type.

To undertake in further detail the ultrastructural analysis of N-Ras distribution, MDCK cells were transfected with constructs encoding green fluorescent protein (GFP) with N-Ras or N-Ras hypervariable region (amino acids 163–189) fused to its C terminus and examined using immunogold electron microscopy with antibodies that recognize the GFP tag. To avoid artifactual localizations caused by overexpression, low levels of expression were chosen, that is, cultures in which Western blotting showed a clear anti-GFP signal but in which an anti-N-Ras signal did not reach a 2-fold increase over the endogenous N-Ras levels (data not shown). GFP-N-Ras was clearly localized in electron-dense areas on the plasma membrane, both at the cell body and tapered cellular processes (Fig. 7, A and B). However, no specific labeling was detectable in caveolae (Fig. 7A, arrow), whereas in cells transfected with GFP-H-Ras, H-Ras was clearly visible in caveolar membranes (Fig. 7C, arrow). The comparative analysis of the subcellular distribution of GFP-N-Ras and GFP-H-Ras showed that both fusion proteins were detectable on electron-dense areas of the plasma membrane. Interestingly, a high density of gold particles was found on the membrane domains that formed the boundary of filopodia (Fig. 7, D–F, arrows). Like GFP-N-Ras, some scattered gold particles of GFP-H-Ras decorated the cytosol in areas rich in intermediate filaments, but in either case, no labeling was observed on rough endoplasmic reticulum membranes (Fig. 7, D and G). Within the cytoplasm, gold particles of GFP-N-Ras immunoreactivity were mainly distributed on the mitochondria (Fig. 7H) and particularly in areas enriched in intermediate filament bundles (Fig. 7G, i). No differences in localization were detected when using GFP-N-Ras hypervariable region when compared with GFP-N-Ras (data not shown).

In light of our data, we proceeded to use H-, K-, and N-Ras inhibitory mutants as tools to investigate how the signals induced by various stimuli and GEFs, resulting in the activation of ERK2, were affected by the differential blockade on the total ERK2 output. As such, NIH3T3 cells were transiently co-transfected with HA-ERK2 and with the H-N17, K-N17, and N-N17 mutants and stimulated with PDGF or with LPA. As shown in Fig. 8A, the activation of ERK2 by PDGF was markedly down-regulated by H-N17 and K-N17 but not by N-N17 (Fig. 8A). On the other hand, all three inhibitory mutants could repress the LPA-induced activation of ERK2, of which K-N17 caused the largest suppression.

In the same fashion, we finally investigated the effects of the
Ras inhibitory mutants in the stimulation of ERK2 by Ras-activating GEFs. To do so, COS-7 cells were co-transfected with HA-ERK2 and the H-N17, K-N17, and N-N17 mutants, in addition to the different GEFs to be tested. Activation of ERK2 by SOS1 was equally blocked by the three inhibitory mutants (Fig. 8B). ERK2 activation by Ras-GRF1 was only repressed by H-N17 but was unaffected by K-N17 and N-N17. A similar situation was observed with Ras-GRF2, but in this case, K-N17 and N-N17 were capable of inducing a noticeable inhibition on ERK2 activation. Interestingly, the stimulatory effects of the Ras exchange factor Cal-DAG I on the activation of ERK2 were completely unaffected by H-N17, K-N17, and N-N17. Conversely, Cal-DAG II behaved similarly to SOS1; its ability to activate ERK2 was equally blocked by the three Ras inhibitory mutants. On the other hand, ERK2 activation by Cal-DAG III was markedly inhibited by H-N17 and to a lesser extent by K-N17 and N-N17. Overall, our results clearly indicated that H-, K-, and N-Ras N17 mutants had distinct inhibitory effects over most of the Ras-activating GEFs described thus far.

To enable us a better interpretation of these results, we ascertained the ability of the different GEFs to stimulate guanine nucleotide exchange on the three Ras isoforms. In full agreement with previous results (15, 29), we found that SOS induced exchange on the three Ras isoforms, and Ras-GRF1 was active solely over H-Ras (data not show). On the other hand, Ras-GRF2 induced a potent GDP/GTP exchange on H-Ras and to a lesser extent on N-Ras and K-Ras (Fig. 8C). In the case of the CAL-DAG family, CAL-DAG II could stimulate a remarkable nucleotide exchange on the three isoforms. On the other hand, CAL-DAG III catalyzed GDP/GTP replacement to a different degree in the three Ras proteins, being most active on H-Ras and least over K-Ras. By contrast, CAL-DAG I was incapable of inducing exchange on any of the three Ras isoforms.

DISCUSSION

In this study we have investigated the inhibitory specificities that H-Ras, K-Ras4B, and N-Ras N17 dominant inhibitory mutants exhibit toward the activation of the wild-type Ras isoforms. We have found that H-N17, K-N17, and N-N17 display remarkable differences in their ability to inhibit the activation of ERK2 and the nucleotide exchange on H-Ras, K-Ras4B, and N-Ras, induced by EGF. A straightforward explanation for these variations would be that the three Ras dominant inhibitory mutants posses different affinities toward
Fig. 8. Effects of Ras inhibitory mutants on ERK2 activation induced by mitogenic stimuli and Ras-activating GEFs. A, effects of Ras inhibitory mutants on the activation of ERK2 induced by mitogens. NIH3T3 cells were transiently transfected with HA-ERK2 (1 μg) and with AU5-tagged H-N17, K-N17, and N-N17 (250 ng of each). Upon stimulation with PDGF (10 ng/ml) or with LPA (10 μM) for 5 min, where indicated, kinase assays were performed as previously described. Lower panel, protein levels of HA-ERK2 as determined by immunoblotting using an HA-specific antibody. B, effects of Ras inhibitory mutants on the activation of ERK2 induced by Ras-activating GEFs. COS-7 cells were transiently transfected with HA-ERK2 (1 μg) and with AU5-tagged H-N17, K-N17, and N-N17 (250 ng of each), in addition to the different GEFs (0.5 μg), where indicated (+). The kinase assays were performed as previously described. C, GDP/GTP exchange induced on H-, K-, and N-Ras by Ras-activating GEFs. Ras GTP loading was determined as described under “Materials and Methods,” in COS7 cells transfected with the indicated GEFs (0.5 μg) and the HA-tagged Ras isoforms (1 μg) as shown. WB, Western blot.

the GEFs activated by EGF. Of all the Ras-activating GEFs described up to date, only SOS 1–2 and Ras-GRF2 are ubiquitously expressed (46, 47). In the experimental model utilized in this study, COS-7 cells, we have not detected expression of Ras-GRF2.2 Furthermore, Ras-GRF2 is essentially activated by G-protein-coupled receptors, not by the tyrosine kinase type, like the EGF receptor (47). Therefore, it is predictable that the EGF-induced events described herein are mainly mediated by SOS, notwithstanding the participation of other, as yet unidentified GEFs.

To the best of our knowledge, a comparative study on the binding affinities that SOS exhibits toward H-, K-, and N-Ras has not been reported. However, major differences are not to be expected. First, regarding the structure, the resolution of the SOS-Ras complex has revealed that the residues in Ras that determine the binding to SOS are highly conserved among H-, K-, and N-Ras (48). Second, any existing differences on the binding affinities of SOS and the three Ras isoforms would be reflected by the efficiency with which SOS stimulates nucleotide exchange in H-, K-, and N-Ras in vitro. As such, it is known that SOS induces GDP/GTP exchange on the three isoforms in the hierarchy H-Ras > N-Ras > K-Ras (29). However, the

recorded variations in the nucleotide replacement induced by SOS on the different Ras isoforms are small.3 This also occurs for other GEFs such as Ras-GRF1. In this case, differences on its exchange potential do not even reach 2-fold between any two Ras isoforms (49). In light of these considerations, it is unlikely that distinct GEF binding affinities can account for the dramatic differences that H-, K-, and N-Ras N17 mutants display in their capacity to inhibit Ras functions in EGF-induced episodes.

An alternative explanation could be found in the recently reported compartmentalization of Ras proteins in distinct plasma membrane domains (25). It has been shown that H-Ras is distributed approximately equally in caveolar and noncaveolar lipid rafts and bulk plasma membrane. On the other hand, K-Ras is localized predominantly in nonraft bulk membrane (26, 31, 45). A recent report also localizes K-Ras in caveolae (27). However, this last conclusion is reached by co-localization with caveolin using confocal microscopy, as opposed to the previous studies that utilize electron microscopy. It is debatable whether confocal microscopy can offer the necessary resolution to discriminate accurately between caveolae and contiguous bulk membrane. Herein, we present for the first time the ultrastructural localization of N-Ras. We have found that N-Ras is mainly present in lipid rafts, in agreement with other investigators.3 However, we have not detected N-Ras in caveolae, in contradiction to a previous report using confocal microscopy (27). Our results indicate that N-Ras also co-localizes with H-Ras in the membrane and tips of cellular prolongations and filopodia. We have also detected N-Ras in mitochondria, in consonance with previous reports (50), something that may be directly related to the steady-state antiapoptotic signal generated by N-Ras (51). Interestingly, some N-Ras co-localizes in the cytoplasm with intermediate filaments, a connection unprecedented thus far. It is likely that the N-Ras associated with mitochondria and intermediate filaments accounts for the portion of N-Ras, about 20%, detected in the last frustions of the sucrose gradients.

Basing ourselves in the above mentioned distribution of the three Ras isoforms in distinct plasma membrane microdo-

2 I. Arozarena and P. Crespo, unpublished results.

3 J. F. Hancock, personal communication.
mains, we propose the model depicted in Fig. 9 to explain our results on the inhibitory properties of H-, K-, and N-Ras N17 dominant inhibitory mutants. As discussed before, H-Ras is present: in caveolae, in noncaveolar lipid rafts where it co-localizes with N-Ras, and in the disordered, bulk plasma membrane where it co-exists with K-Ras. Therefore, it would be conceivable to find H-N17 in all these compartments. On the other hand, the presence of K-N17 would be restricted to bulk membrane, and N-N17 would be solely found in lipid rafts. Although H-Ras is equally present in the three membrane microdomains, there is evidence suggesting that H-Ras activation takes place primarily in caveolae (26, 45, 52–54). Even though the main H-Ras signal may originate in caveolae, the presence of H-Ras in rafts and bulk membrane makes it conceivable that secondary, less intense H-Ras-mediated signals can also arise in these locations, where the respective N-Ras and K-Ras activation takes place as well.

As such, H-N17 would block the activation of H-Ras main signal in caveolae, the activation of an H-Ras secondary signal and of N-Ras in rafts, and the activation of another H-Ras secondary signal and of K-Ras in bulk membrane. This agrees with our data demonstrating that inhibition by H-N17 is greatly rescued by the overexpression of H-Ras wild type, which restores the H-Ras signal in all locations. Conversely, H-N17 inhibition is only slightly rescued by K-Ras (12%), which partially restores the EGF-induced signal generated in bulk membrane, and by N-Ras (16%), which can only re-establish the signal in lipid rafts. On the other hand, K-N17 completely inhibits the activation of K-Ras and partially blocks H-Ras activation (22%), because it can only interfere with the H-Ras-mediated component that originates in bulk membrane. Because K-N17 is not present in lipid rafts, it does not affect N-Ras activation whatsoever. Accordingly, because the K-N17 inhibitory effect is restricted to the bulk membrane, it can be rescued by the overexpression of the Ras isoforms that are located therein, H-Ras and K-Ras itself, as our data demonstrate. Likewise, N-N17 completely inhibits the activation of its wild-type counterpart and blocks the activation of the H-Ras component that operates in lipid rafts (16%). In agreement, we show that the overexpression of wild-type H-Ras and of N-Ras counteracts N-N17 inhibitory effect, which takes place solely in lipid rafts. Because N-N17 is not present in bulk membrane, it does not affect K-Ras activation. Overall, this model reconciles our results about the inhibitory properties of Ras dominant interfering mutants, with the present knowledge on the compartmentalization of Ras isoforms. These data, obtained in COS-7 cells, are strongly validated by our experiments in N-Ras-null fibroblast. In this cellular setting, we demonstrate that the absence of endogenous N-Ras severely precludes N-N17 inhibitory effects, without affecting those of H-N17 and K-N17.

Our results also indicate that the substitution of the farnesyl anchor for a myristoylation signal in H-Ras does not affect the ability of the resulting myristoylated/palmitoylated H-Ras to rescue the inhibitory effect elicited by H-N17. Interestingly, switching the farnesyl anchor for a myristoylation signal also potentiates the competence of N-Ras for counteracting the inhibition exerted by H-Ras N17. A likely explanation for these phenomena is provided by recent reports indicating that myristoylated H-Ras is distributed through the plasma membrane in a similar way to wild-type H-Ras (29). Thus, it is conceivable that myristoylation would alter N-Ras location within the membrane and augment its concentration at sites where it co-localizes with H-Ras, thereby enabling it to counterbalance H-N17 inhibitory effects.

Having established the specificity range for H-, K-, and N-Ras dominant inhibitory mutants, we have used them as tools to investigate the relative contribution of their wild-type counterparts to the signals generated by a series of mitogenic stimuli driven through different types of membrane receptors.

The use of these mutants would also be extremely helpful for identifying the plasma membrane compartment in which these signals are generated. We have shown that the activation of ERK2 by EGF is inhibited by the three Ras inhibitory mutants, but to different extent: almost total inhibition by H-N17, 88% repression by K-N17, and 55% inhibition by N-N17. Because the inhibition brought about by H-N17 results from blocking the signals generated in caveolae, rafts, and bulk membrane, whereas the repression by K-N17 is solely due to the inhibition of the bulk membrane-activated signal, this would suggest that K-Ras is the main Ras isoform conveying the EGF signal to the ERKs cascade. A similar situation is observed in the case of PDGF, which is equally inhibited by H-N17 and K-N17 but is largely unaffected by N-N17, in consonance with previous results indicating that PDGF signals are not efficiently conveyed by N-Ras (55). The prevalence of the bulk membrane K-Ras component is also remarkable in the case of the activation of ERK2 stimulated by LPA, which is repressed most potently by K-N17.

In a similar fashion, we have utilized H-, K-, and N-Ras dominant inhibitory mutants to give us an insight into the sites of action and isoform specificity displayed in vivo by most Ras-activating GEFs described thus far. As such, our data show that the activation of ERK2 by Ras-GRF1 is inhibited by H-N17 but is completely unaffected by K-N17 and N-N17. This result indicates that Ras-GRF1 can only signal through H-Ras, in perfect agreement with previous results showing that, in vivo, Ras-GRF1 induces GDP/GTP exchange in H-Ras but not in K-Ras nor in N-Ras (15). A similar situation is observed for Ras-GRF2: only in this case, K-N17 and N-N17 can slightly diminish the signal elicited by this GEF. These results could be interpreted as Ras-GRF1 inducing the activation of H-Ras solely in caveolae, whereas Ras-GRF2 would be capable of activating, to a lesser extent, the lipid rafts and bulk membrane components of the total Ras signal. Indeed, we demonstrate that Ras-GRF2 is capable of stimulating GDP/GTP exchange on N-Ras and on K-Ras, although at lower levels than on H-Ras.

In the case of CAL-DAG III, its potential to activate ERK2 is remarkably inhibited by H-N17, and to a lesser extent by K-N17 and N-N17, thereby pointing to the H-Ras/caveolar component as the main route used by this GEF for activating ERK2. Also in the case of this GEF, the effects exhibited by the Ras inhibitory mutants on its function match closely its affinity for the three Ras isoforms as demonstrated by in vivo exchange assays. As such, we show that CAL-DAG III is primarily active on H-Ras and exhibits weaker exchange activities on N-Ras and K-Ras.

Particularly intriguing situations are those detected for SOS1 and CAL-DAG II, in these two cases, the three N17 mutants suppress ERK2 activation with similar efficiency. This was unexpected because, in light of our model, if the signals generated in caveolae, rafts, and bulk membrane were equal, H-N17 would be expected to exert a greater inhibition than the other two N17 mutants. Although we do not have a precise answer for this phenomenon, one possible explanation could be that the expression levels of these GEFs are high enough as to overcome the inhibitory effects of the N17 mutants in all locations. A second possibility would be that the Ras dominant inhibitory mutants completely suppress the activation of ERK2 brought about by the total Ras component and the residual activation being due to the stimulation by SOS or...
CAL-DAG II is an ERK-activating pathway mediated by another GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the three Ras isoforms. Nevertheless, our results clearly show that CAL-DAG I can induce a potent ERK2 activation that is insensitive to inhibition by H-N17, K-N17, and N-N17. Because CAL-DAG I is an effective GEF for Rap-1 (16), it is likely that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the three Ras isoforms. Nevertheless, our results clearly show that CAL-DAG I can induce a potent ERK2 activation that is insensitive to inhibition by H-N17, K-N17, and N-N17. Because CAL-DAG I is an effective GEF for Rap-1 (16), it is likely that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56). A similar situation may be occurring in the case of CAL-DAG I. We and others (16) have demonstrated that this GEF cannot induce nucleotide exchange on any of the other GTPase. Indeed, both SOS and CAL-DAG II can stimulate nucleotide exchange on M-Ras, and CAL-DAG II is also active over TC21 (56).